Last edition
News about
UK MHRA Approves Retifanlimab for Merkel Cell Skin Cancer
The UK MHRA has approved retifanlimab (ZYNYZ) for the treatment of advanced Merkel Cell Carcinoma (MCC), a rare and aggressive skin cancer with significant unmet medical need.
Astex and Genentech Partner to Develop Precision Small Molecule Therapies for Breast Cancer
Astex Pharmaceuticals has entered into an exclusive global research and licensing agreement with Genentech to advance small molecule therapies for breast cancer. The deal includes a USD 25 million upfront payment to Astex and potential milestone payments exceeding USD 490 million, alongside tiered royalties on future product sales.
Sanyou Bio, Baiyunshan Xihe Partner to Advance AI-Driven Radiopharmaceutical Development
Sanyou Biopharmaceuticals and Guangzhou Baiyunshan Xihe Health Pharmaceutical have entered a strategic partnership to co-develop innovative radiopharmaceuticals and radiodiagnostic products.
PharmAla Completes GMP Manufacturing for ALA-002
PharmAla has completed GMP manufacturing of ALA-002 drug substance components and is preparing to begin GMP drug product manufacturing for upcoming global clinical trials.
TG Therapeutics Launches Phase 2 Trial of BRIUMVI for Schizophrenia
TG Therapeutics has initiated a Phase 2 trial of BRIUMVI in treatment-resistant schizophrenia, evaluating B-cell depletion as a potential therapy for patients with immune dysfunction.
Opus Genetics Aligns with US FDA on Phase 3 OPGx-LCA5 Trial
Opus Genetics has aligned with the US Food and Drug Administration (FDA) on the Phase 3 trial design for OPGx-LCA5 in inherited retinal disease, with phase 3 dosing expected in Q4 2026 and a potential Biologics License Application (BLA) submission based on 6-month efficacy data.
Astex Partners with Genentech on Breast Cancer Therapy Research
Astex has entered an exclusive research and licensing agreement with Genentech for a breast cancer therapy program, with potential deal value exceeding USD 490 million plus tiered royalties.
AbbVie Wins EU Approval for TEPKINLY in Combination with Lenalidomide and Rituximab
The European Commission has approved AbbVie's TEPKINLY with lenalidomide and rituximab as the first bispecific, chemotherapy-free treatment for Relapsed or Refractory Follicular Lymphoma in the second-line setting.
AtaiBeckley Completes Patient Dosing in Phase 2b Trial of VLS-01 for Treatment-Resistant Depression
AtaiBeckley has completed dosing the final patient in its Phase 2b Elumina trial evaluating VLS-01 for treatment-resistant depression. The company expects topline results in the fourth quarter of 2026 and plans to expand the therapy into major depressive disorder and generalized anxiety disorder, subject to positive clinical outcomes.
Arima Genomics Partners with Active Motif to Expand Global Access to Hi-C Research Solutions
Arima Genomics has granted Active Motif exclusive distribution rights for its Hi-C research kits and services, supporting broader adoption of 3D genomics tools while advancing Arima's clinical cancer diagnostics strategy.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy